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Abstract. Calcium-sensing receptor (CaSR) is a plasma mem-
brane protein that regulates tubular reabsorption of Ca. To
establish its role in idiopathic hypercalciuria, the association of
urinary Ca excretion with the polymorphisms of CASR gene
has been studied in healthy subjects and in hypercalciuric and
normocalciuric Ca stone formers. CASR exon 7 single nucle-
otide polymorphisms (SNP), G/T at codon 986, G/A at codon
990, and C/G at codon 1011, were evaluated by PCR ampli-
fication and direct sequencing in 97 normocalciuric stone
formers, 134 hypercalciuric stone formers, and 101 normocal-
ciuric healthy controls. Four haplotypes were defined on the
basis of CASR gene SNP: haplotype 1 was characterized by the
most frequent sequence; haplotypes 2, 3, or 4 by the presence
of a single polymorphic variant at codon 986, 990, or 1011,
respectively. The relative risk of hypercalciuria was calculated
with multinomial logistic regression and was significantly in-
creased only in individuals carrying haplotype 3 (Odds ratio,
13.0 [95% confidence interval, 1.7 to 99.4]). Accordingly, Ca
excretion was higher in subjects bearing haplotype 3, whereas
those bearing haplotype 2 showed a slight increase of plasma
Ca concentration. Multiple regression analysis showed that
haplotype 3 explained 4.1% of the total variance of Ca excre-
tion and 12.6% of the variance explained by the variables
considered in the study. In conclusion, CASR gene could be a
component of the complex genetic background regulating Ca
excretion. Arg990Gly polymorphism could facilitate activation
of CaSR and increase Ca excretion and susceptibility to idio-
pathic hypercalciuria.
Calcium-sensing receptor (CaSR) is a plasma membrane pro-
tein that regulates parathyroid hormone (PTH) secretion by
parathyroid cells and Ca reabsorption by kidney tubular cells
(1–3). It is activated by the increase of extracellular concen-
tration of Ca ions, which bind to the large extracellular N-
terminal domain of the CaSR molecule (1,2). CaSR exerts its
cellular activity through the stimulation of a G protein by its
intracellular tail (2), which leads to the inhibition of PTH
production (3) and tubular Ca reabsorption (2,4). In addition,
CaSR influences intestinal Ca absorption (5), bone remodeling
(6,7), and even nervous transmission (8).
Inactivating mutations of CASR gene account for disorders
characterized by hypocalciuria and hypercalcemia due to the
altered control of PTH release and tubular Ca reabsorption:
heterozygotes develop benign familial hypocalciuric hypercal-
cemia, whereas homozygotes are affected by severe neonatal
hyperparathyroidism (9,10). Through opposite mechanisms,
mutations enhancing CaSR activity lead to disorders charac-
terized by hypocalcemia and hypercalciuria (11).
Three clustered single nucleotide polymorphisms (SNP),
causing nonconservative amino acid changes, have been de-
scribed on exon 7, encoding the intracellular domain of CaSR
(12,13). The most common SNP consists of the substitution of
a guanine with a thymine at codon 986, leading to the
Ala986Ser variant (12,13). The other two SNP are less fre-
quent: an adenine/guanine substitution at codon 990 deter-
mines the Arg990Gly variant; a cytosine/guanine substitution
at codon 1011 determines the Gln1011Glu variant. The func-
tional effects of these amino acid changes are yet unknown, but
a slight increase of plasma Ca concentrations, not associated
with symptoms, was found in healthy subjects carrying the
986Ser allele (12).
Studies in humans (9) and in canine tubular cells (4) showed
an inhibitory effect of CaSR on cellular Ca transport, suggest-
ing that CaSR plays a key-role in the regulation of Ca excre-
tion. In keeping with these observations, CASR gene has been
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considered a candidate for idiopathic hypercalciuria (14), a
familial disorder predisposing to Ca kidney stones and char-
acterized by increased Ca excretion in the presence of normal
Ca concentrations in plasma (15,16). This view has been con-
trasted by a study in Ca stone-forming French-Canadian sibling
pairs, finding no linkage between idiopathic hypercalciuria and
CASR gene locus (17). However, even though CASR gene may
not be a major determinant in idiopathic hypercalciuria, its
polymorphisms may influence tubular Ca reabsorption capac-
ity. Therefore, in the present study, the association of urinary
Ca excretion with CASR gene SNP was evaluated in an Italian
population of healthy subjects and of hypercalciuric and nor-
mocalciuric Ca stone formers.
Materials and Methods
Patients
Ninety-seven normocalciuric stone formers (65 male patients and
32 female patients; weight, 69  1.2 kg; age, 45  1.5 yr), 134
hypercalciuric stone formers (78 male patients and 56 female patients;
weight, 69  1.1 kg; age, 47  1.1 yr), and 101 normocalciuric
healthy controls (58 male patients and 43 female patients; weight, 72
 1.2 kg; age, 46  1.2 yr) were included in the study. These subjects
were white and were characterized by no polymorphic variants or by
the presence of a polymorphic variant at one single CASR exon 7 SNP.
According to these criteria, six individuals (two healthy subjects, one
normocalciuric, and three hypercalciuric stone formers), who were
double heterozygotes for two CASR exon 7 SNP, were not included
among the subjects enrolled for the study.
Stone formers were recruited at their first visit at the Outpatient
Stone Clinic of San Raffaele Hospital in Milan, Italy. To be included
in the study, stone formers had to have produced at least one Ca
kidney stone and their plasma creatinine, sodium, potassium, and Ca
concentrations had to be normal. All of them had to be able to lower
urinary pH under 5.5. Stones present in patient urinary tract had to
have diameter smaller than 5 mm. None of them had to have obstruc-
tive nephropathy or urinary tract dilatation, evaluated by echographic
examination. Most of the patients (n  150; 65%) were addressed to
the clinic after lithotripsy and were studied at least 3 mo after
lithotriptic treatment. The hospital’s protocol does not include any
pharmacologic treatment for kidney stones immediately after litho-
tripsy, but only dietary counseling (increase of water intake). The
other patients (n  81; 35%) were sent to the Outpatient Clinic by
attending physicians before starting any kind of treatment. In no case
was a patient studied if he or she took any treatment for kidney stones
(thiazide, citrate, or others) for at least 3 mo before the study. No
patient had diseases other than kidney stone, and none took any
long-term medications.
Healthy subjects were selected from the population recruited for
the InCHIANTI study, an epidemiologic survey conduced in Greve
and Bagno a Ripoli, two little towns near Florence. They were
selected according to the following criteria: absence of hypercalciuria,
age between 20 and 60 yr, no clinical diagnosis of hypertension,
diabetes, dyslipidemia, stroke, coronary heart disease, kidney stones,
and no treatment with drugs affecting Ca metabolism, like Ca salts or
vitamin D. The rationale and methods of the InCHIANTI study have
been previously reported (18).
Stone forming and healthy subjects were considered hypercalciuric
when their 24-h Ca excretion was greater than 7.5 mmol in male
patients or 6.25 mmol in female patients or greater than 0.1 mmol/kg
of body weight independently of gender (19).
The study agrees with the indications of the Helsinki Declaration
and was approved by San Raffaele Hospital Ethical Committee. All
subjects gave informed consent to the study and genomic analysis.
Phenotyping
Total plasma concentration of Ca and 24-h Ca excretion were
determined in healthy subjects and in stone-forming patients. In stone
formers, 24-h excretion of phosphates and sodium, serum phosphate,
plasma creatinine, and PTH and intestinal absorption of strontium
were also measured. Intact PTH was determined by immunoradiomet-
ric assay (Nichols Institute). Strontium was used as a surrogate marker
to assess intestinal Ca absorption. Intestinal strontium absorption was
determined after an oral load, as described previously (20). Strontium
(30.2 mol of Sr per kg of body weight) was administered to patients
in distilled water solution as chloride salt after overnight fast. Blood
samples were drawn 60 min after strontium load ingestion, and
strontium concentrations were measured in serum by atomic absorp-
tion spectrophotometer (Perkin-Elmer 4000; Perkin-Elmer, Norwalk,
CT). Ion absorption was calculated as the incremental area (above
baseline) under the serum strontium concentration-time curve, using
the trapezoid method (mmol · L1 · min).
Genotyping
Genomic DNA was isolated from peripheral blood cells by stan-
dard procedures. Mutation screening was carried out by denaturing
gradient gel electrophoresis (DGGE) in hypercalciuric patients. The
entire CASR coding sequence (exons 2 to 7) was amplified by the
PCR. DNA amplification primers for each exon were designed on the
basis of Pearce et al. and Vigouroux et al. (11,21); moreover, one of
the two primers used in each PCR had the proper 5' end GC-tail to
create a high melting temperature domain.
Samples were run on the Bio-Rad DCode denaturing gel electro-
phoresis system for mutation detection (Bio-Rad, Hercules, CA). The
denaturing conditions were from 20% to 80%, whereas acrylamide
concentration ranged from 6% to 10% depending on fragment length.
Electrophoresis was performed at a constant temperature of 60°C at
120 V for 12 h. Gels were stained with ethidium bromide and were
photographed with Kodak Digital Camera (Eastman Kodak, Roches-
ter, NY).
Part of exon 7 of CASR gene, which comprises 3 SNP (G/T at
codon 986, A/G at codon 990, and C/G at codon 1011), were evalu-
ated by PCR amplification and direct sequencing. PCR was carried
out using primers 5'CAGAAGGTCATCTTTGGCAGCGGCA3' and
5'TGCAGACCTGTTTCCTGGACGGTC3', sequences that flank the
polymorphic site giving an amplimer of 206 bp. Purified PCR prod-
ucts served as template for the sequence reaction, which was per-
formed using a ready reaction mix (ABI PRISM Big-Dye Terminator
Cycle Sequencing Ready Reaction Kit, Applied Biosystems, Foster
City, CA) and the same forward primer as for PCR. Sequence prod-
ucts were generated during 25 cycles of the following steps: 15 s at
96°C, 10 s at 50°C, and 2 min at 60°C. Unincorporated dye termina-
tors were removed by ethanol/sodium acetate precipitation. After-
ward, dyed samples were denatured in 20 l of Template Suppression
Reagent (TSR, Applied Biosystems) at 95°C for 10 min and cooled on
ice for 15 min. The ABI PRISM 310 Genetic Analyzer (Applied
Biosystems) was used for capillary electrophoresis. All sequences
were analyzed for comparison using resident software.
Four haplotypes were defined on the basis of exon 7 SNP of CASR
gene (Table 1): they were respectively characterized by the most
common sequence (haplotype 1) or by the presence of one single
polymorphic variant, respectively at 986 (haplotype 2), 990 (haplo-
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type 3) and 1011 (haplotype 4). According to these criteria, six double
heterozygotes at CASR exon 7 SNP were not considered, as already
mentioned. Participants in the study were divided into four groups
according to their haplotypes: group 1 was composed by Ala986,
Azg990, and Gen1011 homozygotes; group 2 was composed by
986Ser homozygotes and Ala986Ser heterozygotes; group 3 was
composed by 990Gly homozygotes and Arg990Gly heterozygotes;
group 4 was composed by Gln1011Glu heterozygotes (Table 1).
Statistical Analyses
Distribution of CASR genotypes was compared in normocalciuric
and hypercalciuric stone formers and healthy subjects by multinomial
logistic regression. Relative risk to be hypercalciuric was estimated by
the calculation of the odds ratio (OR) and its 95% confidence interval
(95% CI).
Quantitative variables were reported in the text as mean  SE.
Differences of the means were tested by t test or one-way ANOVA
with Scheffe’s post-hoc multiple comparisons test.
Dependence of Ca excretion or plasma Ca concentration on CASR
haplotypes was evaluated in stone formers by multiple regression
analysis. To take into account the effect of possible confounders, we
used a two-step multiple regression model in which the confounders
were entered at the first step and CASR haplotypes at the second step.
Statistical analyses were conducted at the   0.05 level and were
two-tailed. All analyses were performed using the SPSS 10 statistical
package (SPSS Inc., Chicago, IL).
Results
Frequency of CaSR Polymorphisms
Preliminary analysis by DDGE showed no abnormal mobil-
ity pattern of CASR gene in either hypercalciuric and normo-
calciuric stone formers, but the already described shifts of exon
7 (data not shown). Genotype frequencies at polymorphic sites
did not deviate from those expected according to Hardy-Wein-
berg equilibrium in both healthy subjects and stone formers.
Furthermore, no linkage disequilibrium was observed among
the three SNP (data not shown). In the whole population,
haplotype 1 represented the most frequent sequence of CASR
gene exon 7.
Participants were divided into four groups, each comprising
homozygotes and heterozygotes for each CASR gene exon 7
haplotype (Table 1). Their distribution is shown in Table 2. To
test the relationship between CASR haplotypes and clinical
classification (healthy subjects, normocalciuric stone formers,
and hypercalciuric stone formers), a multinomial logistic re-
gression was performed with clinical classification as the de-
Table 1. Patients and haplotypesa
n
Base Change Amino Acid Change
986 990 1011 986 990 1011
Group 1 186 Haplotype 1 GCC AGG CAG Ala Arg Gln
Haplotype 1 GCC AGG CAG Ala Arg Gln
Group 2 101 Haplotype 2 TCC AGG CAG Ser Arg Gln
Haplotype 1 GCC AGG CAG Ala Arg Gln
17 Haplotype 2 TCC AGG CAG Ser Arg Gln
Haplotype 2 TCC AGG CAG Ser Arg Gln
Group 3 15 Haplotype 3 GCC GGG CAG Ala Gly Gln
Haplotype 1 GCC AGG CAG Ala Arg Gln
1 Haplotype 3 GCC GGG CAG Ala Gly Gln
Haplotype 3 GCC GGG CAG Ala Gly Gln
Group 4 12 Haplotype 4 GCC AGG GAG Ala Arg Glu
Haplotype 1 GCC AGG CAG Ala Arg Gln
a Healthy controls and stone formers were divided according to their haplotypes for CASR exon 7. Four haplotypes were considered and
defined by the most frequent wild-type sequence (haplotype 1) or by the polymorphic variant for one single SNP (haplotype 2, 3, and 4).
Each polymorphism was assumed dominant, and group membership was assigned to patients carrying one or two alleles for each SNP.
None was homozygous for Gln1011Glu polymorphism. Base and amino acid changes are indicated for each SNP.
Table 2. Distribution of individuals with different CASR haplotypes was compared in healthy subjects and normocalciuric or
hypercalciuric stone formersa
Healthy Subjects Hypercalciurics Stone FormersNormocalciurics Total
Group 1 53 (52.5%) 74 (55.2%) 59 (60.8%) 133 (57.6%)
Group 2 44 (43.6%) 43 (32.1%) 31 (32%) 74 (32.0%)
Group 3 1 (1%) 13 (9.7%) 2 (2.1%) 15 (6.5%)
Group 4 3 (3%) 4 (3%) 5 (5.2%) 9 (3.9%)
a Group composition is displayed in Table 1.
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pendent variable and haplotype group as the factor chosen for
the design. Healthy controls were the reference population in
the analysis. Relative risk to be hypercalciuric (Table 3) was
significantly increased in haplotype 3 subjects (OR, 13; 95%
CI, 1.7 to 99.4).
Association between Haplotypes and Phenotypes in the
Whole Population
The quantitative variables were compared in individuals
with different haplotypes. At first, healthy subjects and stone
formers were considered together (Table 4). Ca excretion was
higher in individuals carrying haplotype 3 (n  16; 9.18 
0.95 mmol/24 h) than in those not carrying haplotype 3 (n 
316; 6.16  0.19 mmol/24 h; P  0.0005, t test). Although
one-way ANOVA showed no significant difference in plasma
Ca concentration between individual groups (Table 4), it was
slightly higher in individuals carrying the haplotype 2 (n 
118; 2.37  0.01 mmol/L) than in those not carrying haplotype
2 (n  214; 2.35  0.01 mmol/L; P  0.047, t test). This
difference was particularly marked in the 17 homozygotes for
haplotype 2 (2.41  0.02 mmol/L; P  0.02 versus individuals
not carrying haplotype 2, t test), whereas their Ca excretion
was not increased (5.46  0.89 mmol/24 h).
Association between Haplotypes and Phenotypes in
Stone Formers
Also when stone formers were considered alone (Table 5),
Ca excretion remained significantly higher in haplotype 3 than
in haplotype 1 patients or when compared with all patients not
carrying haplotype 3 (n  216; 7.23  0.23 mmol/24 h; P 
0.007, t test). Stone formers carrying haplotype 2 had margin-
ally significant higher plasma Ca concentration than those not
carrying haplotype 2 (n  157; 2.35  0.01 mmol/L; P  0.05,
t test). A further increase of plasma Ca was observed in stone
formers homozygous for haplotype 2 (n  8; 2.41  0.01),
whereas urinary Ca excretion (7.06  1.71 mmol/24 h) was not
different from that of other groups.
Forty-three hypercalciuric stone formers carried haplotype
2; their plasma Ca concentration (2.39  0.01 mmol/L) and Ca
excretion (10.38  0.51 mmol/24 h) were higher than in the
other 91 hypercalciuric stone formers (2.35  0.01 mmol/L [P
 0.026] and 9.13  0.26 mmol/24 h [P  0.016, t test],
respectively). Only three homozygotes for haplotype 2 were
detected among hypercalciuric stone formers (plasma Ca: 2.43
 0.02 mmol/L; Ca excretion 11.97  2.54 mmol/24 h).
Multiple Regression
The capacity of CaSR haplotypes to explain variance of Ca
excretion was analyzed by multiple regression in stone form-
ers. Independent variables were entered in the regression
model in two subsequent steps. In the first step, potential
confounders of the association between haplotype and Ca
excretion were entered in the model: namely, they were body
weight, age, plasma Ca, plasma PTH, serum phosphate, plasma
creatinine, intestinal strontium absorption. and sodium excre-
tion. In the second step, haplotype 2 or haplotype 3 was entered
and added to the other independent variables.
Sodium excretion, body weight, plasma creatinine, and en-
teral absorption of strontium associated with Ca excretion (r2
 0.284; F  6.1; P  0.0001). Haplotype 3 significantly
improved the percentage of explained variance by 12.6% (cu-
mulative r2  0.326; F  6.54; P  0.0001; r2 change 
0.041; F change  7.5, P  0.007). Haplotype 2 did not
contribute to the variance of Ca excretion (r2 change  0.007;
F change  1.21; P  0.27). Regression analysis for plasma
Ca was performed with the same model and the same inde-
pendent variables used for calciuria analysis, but including
calciuria at the place of plasma Ca concentrations. No variables
other than haplotype 2 showed significant association with the
plasma Ca concentration (cumulative r2  0.101; F  1.52; P
 0.15; r2 change  0.04; F change5.58, P  0.02).
Discussion
Several pieces of evidence indicate that CaSR plays an
important role in the regulation of tubular Ca reabsorption
(1,2,4). In keeping with these studies, CASR gene has been
proposed as a candidate gene for idiopathic hypercalciuria
(14). However, testing this hypothesis, Petrucci et al. (17)
found no linkage of idiopathic hypercalciuria and Ca nephro-
lithiasis with CASR gene locus when using an affected sib-pair
approach in a French-Canadian population. Indeed, DGGE
analysis of the entire coding sequence of CASR gene failed to
detect abnormal mobility patterns suggestive for mutations in
hypercalciuric patients, with the exception of the already
known SNP on exon 7 (10). Accordingly, a previous DNA
sequencing study found no point mutations of CASR in mem-
bers of French hypercalciuric families (22).
The functional importance of exon 7 polymorphisms has
been suggested by the lower plasma Ca concentration in
healthy subjects carrying the allele 986Ser (12) and by the
lower plasma PTH level in Japanese uremic patients carrying
the allele 990Gly (23). Genetic polymorphisms of CASR exon
7 could account for the phenotype variability of a quantitative
multifactorial trait such as Ca excretion. Therefore, in the
Table 3. Results of multinomial logistic regression in
hypercalciuric and normocalciuric stone formers,
with healthy controls as the reference population in
the analysis
Odds Ratio 95% CI Sig
Hypercalciuric stone formers
haplotype 1 1.40 0.98 to 1.99 0.06
haplotype 2 0.98 0.64 to 1.49 0.92
haplotype 3 13.00 1.7 to 99.4 0.01
haplotype 4 1.33 0.3 to 5.96 0.71
Normocalciuric stone
formers
haplotype 1 1.11 0.77 to 1.61 0.57
haplotype 2 0.71 0.45 to 1.12 0.14
haplotype 3 2.00 0.18 to 22.06 0.57
haplotype 4 1.67 0.40 to 6.97 0.48
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present study, we evaluated the distribution of these SNP in
healthy subjects and in a large cohort of stone formers, com-
prising a high number of hypercalciuric patients. We found that
a polymorphic variant of the CASR gene was associated with
the increase of Ca excretion and could contribute to the Ca
excretion variability in our patients.
Genotypes of exon 7 variants were distributed according to
the Hardy-Weinberg equilibrium both in stone formers and
healthy subjects. Ala986Ser was the most frequent SNP, and its
frequency in our populations was close to that previously
reported in other white populations (12,13,25,26). Haplotype 3
was significantly more frequent in hypercalciuric stone formers
than in normocalciuric patients or healthy subjects, so that it
increased the probability to be hypercalciuric for the carriers.
This suggests that Arg990Gly polymorphism affects Ca excre-
tion, the 990Gly allele predisposing to idiopathic hypercalci-
uria. Indeed, haplotype 3 explains a small but significant pro-
portion of Ca excretion variance in stone formers. It equals
12.6% of the explained variance and 4.1% of the total variance
of urinary Ca excretion, in agreement with its multifactorial
nature (27,28). The low explained variance excludes CASR as
a major gene for idiopathic hypercalciuria (24,29).
Therefore, CASR gene is one of the genetic components
modulating Ca excretion. The minor contribution of CASR
gene to Ca excretion could explain why no linkage was shown
between urinary Ca excretion and CASR locus in a study on
French-Canadian stone-forming sib-pairs (17). However, the
different genetic background in Canadian and Italian popula-
tions could modify the weight of CASR in Ca excretion deter-
mination (24,30). Furthermore, that study could be underpow-
ered for the small genotype relative risk we observed (29). To
reduce the influence of unknown genetic components or un-
evenness with controls, we compared hypercalciuric stone
formers with two normocalciuric groups: healthy subjects and
stone formers (30). Patients and controls were recruited in
different areas: Lombardy and Tuscany. Previous studies with
several polymorphic markers failed to disclose genetic heter-
ogeneity among Italian regions, except for Sardinia (31).
Therefore, our samples of healthy subjects and patients appear
to be representative of Italian population, excluding the risk of
genetic stratification.
The activation of CaSR by extracellular Ca inhibits tubular
Ca reabsorption acting directly on ion transport (2,4). We
propose that the 990Gly allele increases CaSR sensitivity or
response to Ca ions. Accordingly, PTH secretion could be
more inhibited by the 990Gly allele, in agreement with previ-
ous findings in uremic patients (23).
The contribution of Ala986Ser polymorphism to plasma Ca
variance is confirmed in the present study (12). Although not
corrected for serum albumin, plasma Ca was slightly but sig-
Table 4. Urinary Ca excretion and plasma Ca concentration in stone formers and healthy controls considered together and
divided according to the haplotypes of CASR gene
Group 1b Group 2 Group 3 Group 4 F P
n 186 118 16 12
Plasma Ca (mmol/L) 2.35  0.01 2.37  0.01 2.35  0.02 2.38  0.02 1.67 0.17
Urinary Ca excretion
(mmol/24 h)a
6.05  0.22 6.44  0.35 9.18  0.95 5.05  0.86 4.86 0.003
a P  0.05, group 3 versus each other haplotype group by Scheffè post hoc test. No significant difference among groups 1, 2, and 4.
b Group composition is displayed in Table 1.
Table 5. Values of phenotypes were compared in stone formers with different haplotypes of CASR gene
Group 1b Group 2 Group 3 Group 4 F P
n 133 74 15 9
Plasma Ca (mmol/L) 2.35  0.01 2.38  0.01 2.35  0.02 2.38  0.03 1.43 0.24
Urinary Ca excretion (mmol/
24 h)a
6.91  0.26 7.96  0.46 9.68  0.87 6.00  0.91 4.46 0.005
PTH (pg/ml) 35  1.6 37  2.3 40  4.3 36  6.0 0.44 0.72
Plasma creatinine (mg/dl) 0.9  0.02 0.90  0.02 0.94  0.04 1.0  0.07 0.82 0.49
Serum phosphate (mmol/L) 1.04  0.02 1.02  0.03 1.07  0.07 1.02  0.05 0.31 0.82
Urinary phosphate excretion
(mmol/24 h)
27.01  0.84 28.41  1.2 27.73  2.01 27.28  3.48 0.32 0.81
Urinary sodium (mmol/24 h) 171  6.8 171  8.9 169  16.7 208  24.8 0.63 0.59
Enteral Sr absorption
(mmol  L1  min)
10.1  0.34 11.5  0.63 11.9  0.93 1.07  0.32 1.53 0.21
a P  0.05 group 3 versus group 1 by Scheffè post hoc test. No other significant differences among groups.
b Group composition is displayed in Table 1.
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nificantly higher in individuals carrying 986Ser allele. This
association suggests that the inhibitory activity of CaSR on
tubular Ca reabsorption and PTH secretion be depressed in
subjects carrying haplotype 2 (1). In spite of these effects, the
increase of plasma Ca was coupled with elevated Ca excretion
in hypercalciuric patients carrying haplotype 2. A possible
interpretation of these findings is that the decreased tubular Ca
reabsorption, characterizing hypercalciuric patients, could
overcome the enhancing effect of haplotype 2 on tubular Ca
transport. In addition, the larger glomerular filtration of Ca,
associated with increased Ca concentration in blood, could
facilitate Ca loss in these patients (1,4). Conversely, in normo-
calciuric subjects carrying haplotype 2, the increase of filtered
Ca could be balanced by the increased reabsorptive capacity.
Previous studies revealed that patients with idiopathic hy-
percalciuria exhibited a decreased axial and peripheral bone
density (32,33), increased bone resorption (34), and histologic
features of high bone turnover (35). These findings suggest that
an abnormality in bone remodeling could be involved in the
mechanisms leading to excessive Ca excretion. Polymorphisms
of CASR gene could exert a direct influence on Ca metabolism
in bone cells (6,7), and two studies demonstrated the associa-
tion of CASR gene polymorphisms with mineral density at
different bone sites (26,36). This suggests a potential role of
CASR gene variants on bone reabsorption in idiopathic
hypercalciuria.
Enteral absorption of Ca is typically increased in hypercal-
ciuric patients (26) and could be influenced by CaSR as well
(5). Its alteration was proposed as the primary event in hyper-
calciuria (16), but our results do not support any relation
among CASR gene polymorphisms and intestinal Ca absorp-
tion, tested using strontium as a surrogate marker.
In conclusion, CASR gene could be considered as a compo-
nent of the genetic background regulating Ca excretion.
Arg990Gly polymorphism could produce a gain-of-function
for CaSR that could increase Ca excretion and the susceptibil-
ity to idiopathic hypercalciuria. Ala986Ser polymorphism ap-
pears to affect Ca concentration in blood, possibly through a
decrease in CaSR activity, which could cause a further increase
of Ca excretion in hypercalciuric patients. Future studies will
attempt to evaluate the function of these polymorphisms
through in vitro analyses.
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